Reuters logo
BRIEF-Vertex Announces Positive Results From Open-Label Phase 3 Study Of KALYDECO(ivacaftor)
December 7, 2017 / 1:22 PM / in 3 days

BRIEF-Vertex Announces Positive Results From Open-Label Phase 3 Study Of KALYDECO(ivacaftor)

Dec 7 (Reuters) - Vertex Pharmaceuticals Inc:

* VERTEX ANNOUNCES POSITIVE RESULTS FROM OPEN-LABEL PHASE 3 STUDY OF KALYDECO® (IVACAFTOR) IN CHILDREN WITH CYSTIC FIBROSIS AGES 1 TO 2 YEARS

* VERTEX PHARMACEUTICALS - KALYDECO​ ‍STUDY MET PRIMARY SAFETY ENDPOINT, SHOWED IMPROVEMENTS ACROSS MULTIPLE ENDPOINTS

* VERTEX PHARMACEUTICALS - ‍ARRIVAL STUDY GENERALLY WELL TOLERATED, SAFETY DATA WERE CONSISTENT WITH THOSE SEEN IN PREVIOUS PHASE 3 STUDIES OF IVACAFTOR​

* VERTEX PHARMACEUTICALS INC - ‍VERTEX PLANS TO SUBMIT APPLICATIONS FOR IVACAFTOR TO FDA AND EMA IN Q1 OF 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below